抗纤维化治疗对特发性肺纤维化患者肺癌发生的影响
这项多中心回顾性研究纳入345例特发性肺纤维化(IPF)患者,比较接受与未接受抗纤维化治疗者的肺癌发生情况。结果显示,接受抗纤维化治疗的患者肺癌发病率和患病率显著更低,肺癌相关死亡率也显著更低,提示抗纤维化治疗可能与降低IPF患者肺癌发生风险相关,并可能部分解释其生存获益。
要点
- 接受抗纤维化治疗的IPF患者肺癌发病率与患病率显著低于未接受者。
- 接受抗纤维化治疗的IPF患者肺癌相关死亡率显著更低。
- 抗纤维化治疗可能与降低IPF患者肺癌发生风险相关。
核心结论
- 抗纤维化治疗可能与特发性肺纤维化患者肺癌发生风险降低相关,并可能部分与其生存获益有关。
研究设计与样本
- 多中心回顾性研究,纳入345例特发性肺纤维化患者,比较接受与未接受抗纤维化治疗者的肺癌发生情况。
主要发现
- 接受抗纤维化治疗的IPF患者肺癌发病率显著低于未接受者。
- 接受抗纤维化治疗的IPF患者肺癌患病率显著低于未接受者。
- 接受抗纤维化治疗的IPF患者肺癌相关死亡率显著低于未接受者。
临床怎么用
- 在管理IPF患者时,可将抗纤维化治疗对肺癌发生风险的潜在影响纳入综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.
引用
- Naoi H, Suzuki Y, Mori K, et al. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. Thorax. 2022. PMID: 35354649. doi:10.1136/thoraxjnl-2021-218281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。